



**HAL**  
open science

## Targeting the AMPK pathway for the treatment of Type 2 diabetes.

Benoît Viollet, Louise Lantier, Jocelyne Devin-Leclerc, Sophie Hébrard, Chloé Amouyal, Rémi Mounier, Marc Foretz, Fabrizio Andreelli

► **To cite this version:**

Benoît Viollet, Louise Lantier, Jocelyne Devin-Leclerc, Sophie Hébrard, Chloé Amouyal, et al.. Targeting the AMPK pathway for the treatment of Type 2 diabetes.. *Frontiers in bioscience: a journal and virtual library*, 2009, 14, pp.3380-400. inserm-00367501


**HAL Id: inserm-00367501**

**<https://inserm.hal.science/inserm-00367501>**


Submitted on 11 Mar 2009

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



**Figure 3.** AMPK and the regulation of skeletal muscle metabolism. Proposed model for the role of AMPK in the regulation of lipid and glucose metabolism in skeletal muscle. AMPK activity may be increased by an altered energy nucleotide or by hormonal action. This activation of AMPK may result in an increase in glucose transport as well as an increase in fatty acid oxidation. ACC, acetyl-CoA carboxylase; AMPK, AMP-activated protein kinase; AS160, Akt substrate of 160kDa; CPT1- $\alpha$ , carnitine palmitoyl transferase-1; Glut4, glucose transporter 4; MCD, malonyl-CoA decarboxylase; PGC1 $\alpha$ , PPAR $\gamma$  co-activator 1 $\alpha$ ; LCACoA, Long Chain acyl CoAs.



**Figure 4.** AMPK and the regulation of hepatic metabolism. Activation of AMPK leads to the inhibition of cholesterol synthesis by the phosphorylation of HMG-CoA reductase. By inhibiting ACC and activating MCD, AMPK increases fatty acid oxidation via the regulation of malonyl CoA levels, which is both a critical precursor for biosynthesis of fatty acids and a potent inhibitor of CPT-1, the shuttle that controls the transfer of LCACoA into the mitochondria. AMPK inhibits hepatic glucose production via the phosphorylation of TORC2 and inhibition gene expression for key gluconeogenic enzymes, G6Pase and PEPCK, and for the transcriptional co-activator PGC-1 $\alpha$ . ACC, acetyl-CoA carboxylase; AMPK, AMP-activated protein kinase; CPT1- $\alpha$ , carnitine palmitoyl transferase-1; G6Pase, glucose-6-phosphatase; LCACoA, Long Chain acyl CoAs; MCD, malonyl-CoA decarboxylase; PEPCK, phosphoenolpyruvate carboxykinase; PGC1 $\alpha$ , PPAR $\gamma$  co-activator 1 $\alpha$ ; TORC2, transducer of regulated CREB activity 2.